| scholarly article | Q13442814 |
| P2093 | author name string | Eriksson P | |
| P2860 | cites work | Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 |
| B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders | Q34797835 | ||
| Treating human autoimmune disease by depleting B cells | Q34848963 | ||
| The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets | Q35111838 | ||
| Current Attitudes to the Therapy of Vasculitis | Q35540941 | ||
| Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion | Q35551028 | ||
| A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies | Q42163521 | ||
| Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease | Q43808460 | ||
| Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy | Q43837378 | ||
| An open study of B lymphocyte depletion in systemic lupus erythematosus | Q44183280 | ||
| Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis | Q44541019 | ||
| The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. | Q54791103 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 540-548 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab | |
| P478 | volume | 257 |
| Q34065598 | Advances in the use of biologic agents for the treatment of systemic vasculitis |
| Q80689377 | Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects |
| Q49691317 | Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q55340553 | Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy. |
| Q34514813 | B-cell targeting in rheumatoid arthritis and other autoimmune diseases |
| Q37369906 | B-cell-directed therapy for inflammatory skin diseases |
| Q38159787 | B-cell-targeted therapy in adult glomerulonephritis |
| Q38576234 | Biologic therapy for refractory scleritis: a new treatment perspective |
| Q45964920 | Biologic therapy in primary systemic vasculitis of the young. |
| Q87393401 | Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis |
| Q37324885 | Churg-Strauss syndrome: 2005-2008 update |
| Q84675179 | Clinical Manifestations and Treatment of Wegener's Granulomatosis |
| Q36358081 | Clinical use of biologics in vasculitis syndromes |
| Q27486517 | CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis |
| Q36623061 | Current pharmacotherapy for the treatment of crescentic glomerulonephritis |
| Q35065425 | Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab |
| Q33602540 | Diabetes insipidus as a complication of Wegener's granulomatosis and its treatment with biologic agents |
| Q36577151 | Drug insight: rituximab in renal disease and transplantation |
| Q37546823 | Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature |
| Q33757209 | Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series |
| Q37640836 | Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis |
| Q37311093 | Hematopoietic stem cell transplantation (HSCT) for primary systemic vasculitis and related diseases |
| Q50598390 | Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. |
| Q36787732 | Indications for biotherapy in systemic vasculitides |
| Q35953330 | Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide |
| Q79799383 | Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? |
| Q83978369 | Long-term follow-up of different refractory systemic vasculitides treated with rituximab |
| Q52915030 | Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis. |
| Q35887318 | Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab |
| Q37254545 | Molecularly targeted therapies for dysimmune neuropathies |
| Q81096216 | Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q36986050 | Off-label uses of rituximab in dermatology |
| Q28390438 | Pathogenesis of ANCA-associated Vasculitis |
| Q37483910 | Pharmacotherapy of vasculitis. |
| Q36458145 | Primary systemic vasculitis: treatment of difficult cases |
| Q37879814 | Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. |
| Q50850119 | Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. |
| Q57945954 | References |
| Q34176634 | Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments? |
| Q35662018 | Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. |
| Q34075484 | Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q37144563 | Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial |
| Q47581564 | Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center |
| Q35557092 | Rituximab for the treatment of Churg-Strauss syndrome with renal involvement |
| Q53481600 | Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. |
| Q33378620 | Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks |
| Q42539284 | Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis |
| Q37132818 | Severe hemorrhagic cystitis associated with prolonged oral cyclophosphamide therapy: case report and literature review |
| Q36504479 | Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? |
| Q36906003 | Small-vessel vasculitis: therapeutic management |
| Q34244998 | Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab |
| Q43267320 | Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab |
| Q47949986 | Successful treatment of severe juvenile microscopic polyangiitis with rituximab |
| Q42955730 | Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome |
| Q37052724 | Targeted biologic approaches to the treatment of systemic vasculitis |
| Q37302795 | Targeting the B cell in vasculitis |
| Q56907441 | Terapias biológicas en las enfermedades autoinmunes sistémicas: ¿se cumplen las expectativas? |
| Q36530278 | The emerging role of rituximab in organ transplantation |
| Q33377109 | The potential utility of B cell-directed biologic therapy in autoimmune diseases |
| Q37950904 | The role of biologics in treatment of ANCA-associated vasculitis |
| Q46932533 | Therapy for vasculitic neuropathies |
| Q37912214 | Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? |
| Q39314270 | Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q36535231 | Wegener's granulomatosis: is biologic therapy useful? |
| Q84118090 | [Anti-B-cell strategies in vasculitides and collagenoses] |
| Q80516806 | [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] |
| Q84600760 | [Results of biological treatments in autoimmune diseases] |
Search more.